S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
C4 Therapeutics, Inc. (CCCC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.61 |
| Open | 6.80 |
| Bid | 6.29 x 2200 |
| Ask | 6.86 x 900 |
| Day's Range | 6.28 - 6.93 |
| 52 Week Range | 6.20 - 51.21 |
| Volume | |
| Avg. Volume | 1,032,660 |
| Market Cap | 324.333M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.81 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.64 |
- GlobeNewswire
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT8634, an orally bioavailable BiDAC™ degrader targeting BRD9 for the treatment of SMARCB1-perturbed cancers, includin
- Zacks
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C – – Phase 1/2 Clinical Trial Initiated for CFT8634, a BRD9 Degrader, for Patients with Synovial Sarcoma and SMARCB1-null Solid Tumors – – Potential of TORPEDO® Platform Demonstrated at AACR with Pre-clinical Presentations on CFT7455, CFT8634 and CFT1946 – – Cash, Cash Equivalents and Marketable Securities Total $421.7 million as of
